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DOI 10.1016/j.ccr.2010.03.018SUMMARYChromosomal rearrangements fusing the androgen-regulated gene TMPRSS2 to the oncogenic ETS tran-
scription factor ERG occur in approximately 50% of prostate cancers, but how the fusion products regulate
prostate cancer remains unclear. Using chromatin immunoprecipitation coupled with massively parallel
sequencing, we found that ERG disrupts androgen receptor (AR) signaling by inhibiting AR expression,
binding to and inhibiting AR activity at gene-specific loci, and inducing repressive epigenetic programs via
direct activation of the H3K27 methyltransferase EZH2, a Polycomb group protein. These findings provide
a working model in which TMPRSS2-ERG plays a critical role in cancer progression by disrupting lineage-
specific differentiation of the prostate and potentiating the EZH2-mediated dedifferentiation program.INTRODUCTION
Prostate cancer is the most common non-skin cancer and
a leading cause of cancer-related deaths in American men. We
and others have previously characterized chromosomal rear-
rangements fusing the androgen-regulated gene TMPRSS2 to
ETS transcription factors such as ERG and ETV1 in a majority
of prostate cancers (Perner et al., 2006; Soller et al., 2006; Tom-
lins et al., 2005; Yoshimoto et al., 2006). Among these, fusions of
TMPRSS2 to the oncogenic ETS transcription factor ERG occur
most frequently, accounting for 40%–80% of prostate cancers
(Clark et al., 2007; Hermans et al., 2006). ERG has also beenSignificance
Despite its high prevalence in prostate cancer, the TMPRSS2-E
downstreammutations emanating fromAR signaling. Here we
modifications in prostate cancer. Although AR was found to ac
we found that ERG binds to AR and a majority of AR target gen
the PcG protein EZH2 facilitating a stem-cell-like dedifferentiat
in cancer by abrogating lineage-specific differentiation of the p
wide location analyses related to AR and TMPRSS2-ERG thatimplicated in recurrent gene fusions found in Ewing’s sarcoma
and acute myeloid leukemia (Hsu et al., 2004; Oikawa and
Yamada, 2003). Knockdown of ERG in VCaP prostate cancer
cells inhibits cell growth, cell invasion, and xenograft tumor
growth (Tomlins et al., 2008; Wang et al., 2008). Overexpression
of ERG increases cell invasion in vitro (Tomlins et al., 2008; Wang
et al., 2008), and induces prostate cancer precursor-like lesions
in mice (Klezovitch et al., 2008; Tomlins et al., 2008). Further-
more, ERG collaborates with genetic lesions of the PI3K path-
way to promote prostate cancer progression in mouse models
(Carver et al., 2009; King et al., 2009; Zong et al., 2009). Although
it is clear that ERG may possess oncogenic properties, it hasRGgene fusionwas thought tomerely represent one ofmany
mapped the genomic landscape of AR, ERG, and key histone
tivate genetic programs involved in prostate differentiation,
es disrupting androgen signaling. In addition, ERG activates
ion program. Thus, TMPRSS2-ERG plays a fundamental role
rostate. Furthermore, we provide a compendium of genome-
will be useful to the research community.
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ERG Disrupts AR Lineage-Specific Differentiationbeen much less clear as to how ERG promotes prostate cancer
progression. Given the prevalence and recurrence of TMPRSS2-
ERG in prostate cancer, we hypothesized that it plays an essen-
tial role in prostate tumorigenesis.
We have earlier demonstrated that ERG induces metallopro-
teinase and plasminogen activator pathway genes such as
MMP3, PLAT, and PLAU (Tomlins et al., 2008). ERG is a member
of the ETS family transcription factors that specifically bind to
genomic regions containing the core GGA(A/T) motifs (Nye
et al., 1992). Interestingly, ETS motifs were found enriched in
the androgen receptor (AR) binding sites determined by chro-
matin immunoprecipitation (ChIP)-on-chip analysis and ETS1,
another member of the ETS family transcription factors, was
shown to physically interact with AR (Massie et al., 2007). More-
over, recent studies revealed that ERG represses the expression
of the prostate-specific antigen (PSA) (Sun et al., 2008), while
ETV1 induces PSA expression (Shin et al., 2009). The molecular
crosstalk between ERG and AR, however, remains largely
uncharacterized.
AR belongs to a family of nuclear transcription factors that
mediate the action of steroid hormones. Cytoplasmic AR,
when bound by androgen, translocates to the nucleus and binds
to the 15-bp palindromic androgen response elements (ARE)
on target genes (Heemers and Tindall, 2007). AR is paramount
for the lineage-specific differentiation of the prostate, inducing
the expression of prostate-specific genes such as PSA and
TMPRSS2, and maintaining the differentiated prostate epithelial
phenotype (Wright et al., 2003). Cellular dedifferentiation, by
contrast, is a hallmark of malignant transformation. Previous
studies have shown that a majority of metastatic prostate tumors
have upregulated expression of the Polycomb group (PcG)
protein EZH2, which plays critical roles in maintaining the undif-
ferentiated state of embryonic stem (ES) cells via catalyzing
H3K27 trimethylation (Lee et al., 2006; Varambally et al., 2002).
EZH2 overexpression in advanced prostate cancer leads to
epigenetic silencing of developmental regulators and tumor
suppressor genes, subverting cancer cells to a stem-cell-like
epigenetic state (Yu et al., 2007b).
Here we employed chromatin immunoprecipitation coupled
with massively parallel sequencing (ChIP-Seq) (Barski et al.,
2007; Johnson et al., 2007; Mikkelsen et al., 2007) to systemat-
ically map the genomic landscape of four transcription factors
and eight histone marks across multiple prostate cancer cell
lines as well as tissues (summarized in Table S1 available online).
Integrative genomic analysis was undertaken to delineate the
interactions among TMPRSS2-ERG, AR, and EZH2. In addition,
we examined the mechanisms of TMPRSS2-ERG in prostate
tumorigenesis in the context of AR-induced prostatic differentia-
tion and EZH2-mediated cellular dedifferentiation.
RESULTS
Genomic Landscape of AR in Prostate Cancer
To determine AR binding sites across the human genome, we
performed ChIP-Seq analysis of the LNCaP prostate cancer
cells treated with either vehicle or saturating amounts of syn-
thetic androgen R1881 as previously reported (Wang et al.,
2007). To evaluate the reproducibility of the ChIP-Seq assay,
we compared the distribution of sequencing reads mapped in444 Cancer Cell 17, 443–454, May 18, 2010 ª2010 Elsevier Inc.every 25 bp bin across the entire genome and observed substan-
tial overlap between technical as well as biological replicates
(Figure S1A). Using the HPeak program (http://www.sph.umich.
edu/csg/qin/HPeak/), we identified enriched binding peaks from
mappable sequencing reads. In LNCaP cells our study revealed
37,193 AR binding peaks, which include 82% of the AR-bound
sites previously reported by ChIP-on-chip assay (Wang et al.,
2009). Importantly, known AR binding sites, such as the
enhancer upstream to the FKBP5 gene, showed marked ChIP-
Seq enrichment comprised of thousands of sequencing reads.
By sorting the binding peaks by height, the top AR-bound genes
included FKBP5, C6ORF81, TACC2, CUTL2, and SLC43A1, all
of which showed ‘‘prostate-specific’’ expression based on the
International Genomics Consortium’s expO microarray data
set profiling 28 tumor types (www.oncomine.com) (Figure S1B).
These genes also ranked among the top ten AR-bound genes in
the VCaP prostate cancer cells that harbor the TMPRSS2-ERG
gene fusions (Tomlins et al., 2005). Approximately 61% of the
AR binding sites in the VCaP cells physically overlapped with
those in LNCaP, suggesting shared as well as cell-type-specific
AR recruitment (Figure 1A). The shared AR binding targets
were further confirmed by the inclusion of previously reported
androgen-sensitive 50 partners of gene fusions in prostate can-
cer such as TMPRSS2,SLC45A3, andC15ORF21 (Tomlins et al.,
2007) (Figure S1C). By contrast, no AR binding was detected on
the androgen-insensitive 50 fusion partner gene HNPRA2B1 that
is constitutively active, supported by the enrichment of two
markers of active transcription, histone H3 lysine 4 trimethylation
(H3K4me3) and RNA polymerase II (RNA PolII), on its promoter.
AR recruitment to these genetic loci was further confirmed
by ChIP polymerase chain reaction (PCR) using gene-specific
primers. Analysis of cell-type-specific AR binding revealed
much higher false-negative rate of ChIP-Seq in VCaP than in
LNCaP, partially accounting for the lesser amount of AR binding
sites detected in the former (Figure S1D). We next examined
the presence of consensus sequence motifs in the AR binding
sites. Out of all 508 predefined motifs of vertebrate transcription
factors (www.genomatix.de), the 15 bp canonical ARE, as
expected, was the most enriched. In addition, the occurrence
of the ARE motif was positively correlated with the height of
ChIP-Seq binding peaks (r = 0.87, p < 0.001) and some binding
peaks contained multiple AREs (Figure S1E). By categorizing all
AR binding sites based on whether they contained a full or half or
no ARE motifs, we found that the binding sites containing full
ARE motifs had significantly (p < 0.001 by t test) higher enrich-
ment peaks than those with half ARE motifs, which had higher
peaks than those without any ARE motifs, supporting the role
of ARE in recruiting AR. Furthermore, de novo motif search using
the MEME program (Bailey and Elkan, 1994) identified a refined
ARE motif that was markedly similar to the canonical ARE (Fig-
ure 1B). Surprisingly, the ETS family motifs were the second-
most enriched motifs suggesting potential colocalization of
ERG with AR (Table S2). Approximately 40% of all AR binding
sites contained at least one ARE motif and about 29% contained
an ETS motif, both being significantly (p < 0.001 by Fisher’s exact
test) more than their respective occurrence in control sequences
(Table S3).
To obtain a functional taxonomy of the AR-bound genes,
we performed molecular concept map (MCM) analysis for
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Figure 1. Genome-wide Location Analysis
of AR in Prostate Cancer
(A) Venn diagram showing overlap of the ChIP-Seq
AR binding sites in the LNCaP and VCaP prostate
cancer cells.
(B) The consensus motif identified in the AR
binding sites. De novo motif search was performed
using the MEME program (Bailey and Elkan, 1994).
(C) An enrichment network linking AR, TMPRSS2-
ERG pathways, and the polycomb-mediated
dedifferentiation program. AR-bound genes
(purple node with black ring) were derived by
ChIP-Seq in the VCaP cells and analyzed by the
MCM in Oncomine. Each node represents one
molecular concept or gene set with node size
proportional to the number of genes. Each edge
represents a statistically significant (p < 13 1010)
overlap of genes in the two linked nodes. Molec-
ular concepts were grouped into five major clus-
ters indicated by oval rings of distinct color. See
also Figure S1 and Tables S1–S4.
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ERG Disrupts AR Lineage-Specific Differentiationenrichment of the AR-bound genes in thousands of pre-defined
molecular concepts/gene sets in the Oncomine database (www.
oncomine.com). Out of approximately 20,000 molecular con-
cepts, a total of 1,462 (7%) showed significant (p < 0.001) enrich-
ment (Table S4). Not surprisingly, AR-bound genes in the VCaP
cells significantly overlapped with those in the LNCaP cells
(p < 1.0 3 10100) and they both related to genes that are regu-
lated by androgen in vitro or in vivo (p < 1.03 1010) (Figure 1C).
In addition, there was significantly enriched AR binding on
‘‘genes underexpressed in metastatic or high-grade tumors’’
(p < 4.0 3 1015), confirming reduced androgen signaling in
aggressive prostate tumors. Importantly, AR-bound genes
were significantly enriched in a number of ERG-regulated gene
sets (p < 4.0 3 1013), indicating an interesting link between
ERG regulation and androgen signaling. Notably, a group of
most significantly enriched (p < 1.0 3 1020) concepts related
to stem cell gene signatures, including target genes of Polycomb
group proteins and H3K27me3 in embryonic stem cells and
metastatic prostate cancers (Boyer et al., 2006; Lee et al.,
2006; Yu et al., 2007b), further connecting the AR and ERG
pathways to PcG-mediated epigenetic silencing and cellular
dedifferentiation.
ERG Occupancy of AR Target Genes in Prostate Cancer
To characterize the potential links among the transcriptional
pathways of AR, ERG, and epigenetic modifications, we per-
formed ChIP-Seq analysis of ERG and a number of key histoneCancer Cell 17, 443–4marks in prostate cancer (Table S1).
Approximately 42,000 ERG binding sites
were identified in the VCaP cells includ-
ing known ERG target genes such as
PLAU, PLAT, MMP3, and MMP9 (Tom-
lins et al., 2008) (Figure 2A). By contrast,
only 608 binding sites were detected in
the ERG-negative LNCaP cells. Interest-
ingly, ChIP-Seq analysis of the RWPE
benign prostate epithelial cells withstable ERG overexpression (RWPE+ERG) identified 6685 ERG
binding sites, 58% of which overlapped with those detected in
the VCaP cells (Figure 2B). Unlike AR, which was mostly enriched
at distal enhancers, ERG primarily bound to the promoter
regions of target genes (Figure 2C and Figure S2). Not surpris-
ingly, the ETS family motifs were the most significantly enriched
motifs in the ERG binding sites (Table S2) and MEME analysis
discovered a de novo ERG motif that was strikingly similar to
the consensus ETS motifs (Figure 2D).
To test the hypothesis that AR and ERG co-occupy target
genes, we analyzed the overlap in their binding sites in every
25 bp bin across the entire genome. Although 61% of the AR-
bound regions in the VCaP cells overlapped with those in
LNCaP, approximately 44% of these sites, surprisingly, also
recruited ERG (Figure 3A). This overlap between AR and ERG
binding sites is remarkable, because AR and ERG each bound
to only 0.1% and 0.7% sequences of the entire genome, respec-
tively. To evaluate this overlap statistically, we compared AR and
ERG binding sites with those of NRSF, a neural specific tran-
scription factor that has not been associated with either AR or
ERG (Johnson et al., 2007). Importantly, there was less than
2% of overlap. The overlap between the AR and ERG binding
sites was significantly more than their overlap with NRSF (p <
0.0001 by Fisher’s exact test). Further, we compared the binding
sites of AR and ERG with other transcription factors and epige-
netic marks analyzed by ChIP-Seq in both LNCaP and VCaP
cells (Figure S3A and Table S5). As expected, we observed54, May 18, 2010 ª2010 Elsevier Inc. 445
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Figure 2. ChIP-Seq Analyses of ERG Binding Sites in Prostate Cancer
(A) ChIP-Seq analysis of the VCaP cells detected ERG binding to previously reported target genes (Tomlins et al., 2008).
(B) Venn diagram showing overlap between the ERG binding sites identified in the VCaP cells and the RWPE+ERG cells. The RWPE cells were infected with
lentivirus overexpressing ERG or lacZ and selected for stable clones. ChIP-Seq of ERG was performed in the stable RWPE+ERG cells using the RWPE+lacZ
as control.
(C) Distribution of AR or ERG binding sites relative to the transcriptional start sites (TSS) of all RefSeq genes. The y axis on the left and right represents the density
of ERG (ERG BS) and AR binding sites (ARBS), respectively. See also Figure S2.
(D) The consensus sequence motif identified in the ERG binding sites by the MEME program.
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ERG Disrupts AR Lineage-Specific Differentiationsubstantial overlap of the same factor across cell types. Remark-
ably, the overlap between AR and ERG in the VCaP cells was
among the highest in all overlaps between different regulators,
including those between AR and FoxA1, PolII, H3K4me1,
H3K4me3, H3K9me3 and H3K27me3. The next strongest over-
lap was of AR with FoxA1and Ace-H3, both of which have
been previously reported (Jia et al., 2008; Lupien et al., 2008).
By assigning ChIP-Seq binding sites to their nearest genes, we
found that ERG is in fact recruited to over 90% of the AR-bound
genes (Figure 3B). This cobinding was further confirmed by
re-ChIP-Seq experiment first using an antibody against ERG fol-
lowed by an antibody against AR (Figure 3C). To further validate
this, we randomly selected a set of five genes that bound both
AR and ERG, including NDRG1, C60rf81, CUTL2, LOC400451,
and ZBTB16 (Figure 3D and Figure S3B). Importantly, using
gene-specific primers, we confirmed AR and ERG co-occu-
pancy on all selected genes by conventional ChIP-PCR assays
(Figure 3E). In addition, the expression of these genes was found
to be differentially regulated by both androgen stimulation and
ERG RNA interference (Figure S3C).
To confirm the interconnected pathways of ERG and AR in vivo,
we performed ChIP-Seq analysis of a human prostate tumor that
expressed both ERG and AR, and identified 6,967 ERG and446 Cancer Cell 17, 443–454, May 18, 2010 ª2010 Elsevier Inc.12,036 AR binding sites, respectively. Not surprisingly, they
both overlapped significantly with their respective binding sites
identified in prostate cancer cell lines (p < 0.001 by Fisher’s exact
test). Importantly, a comparison of the AR- and ERG-binding sites
in the prostate tumor specimen revealed a remarkable overlap
(44%) that is comparable to that (43.97%) observed in the
VCaP cell line model (Figure 3F). MCM analysis of the 1534 tissue
ERG-bound genes revealed a core transcriptional regulatory
circuitry composed of biological correlates with highly significant
overlaps (p < 1.0 3 1090); these include ERG-bound and AR-
bound genes in tumors, ERG-bound and AR-bound genes in
the VCaP cells, AR-bound genes in the LNCaP cells, and ERG-
bound genes in the stable RWPE+ERG cells (Figure S3D).
Next, we determined if ERG and AR physically interact. Coim-
munoprecipitation assays demonstrated an endogenous inter-
action between the AR and ERG proteins in cell line as well as
prostate cancer tissues (Figure 3G and Figure S3E). Using
ethidium bromide preincubation to deplete DNA, we demon-
strated that the interaction between AR and ERG was DNA
independent. Further, in vitro protein-protein interaction assays
revealed that AR directly bound to the ETS domain of the ERG
protein (Figure 3H and Figure S3F). This interaction was further
pinpointed to the C-terminal half (ETS-3) of the ETS domain.
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Figure 3. ERG and AR Co-occupancy of Target Genes in Prostate Cancer
(A) Overlap between the binding sites of different regulators. Significance of overlap was measured relative to their respective overlap with the NRSF binding sites.
*p < 0.05, **p < 0.01, and ***p < 0.001 by hypergeometric test.
(B) ERG binds to a majority of the AR-bound genes. AR or ERG ChIP-Seq binding sites were each assigned to the nearest gene on the genome to derive the list of
bound genes.
(C) Overlap between the ERG-bound genes and the genes that are bound by both AR and ERG as determined by re-ChIP-Seq using an anti-ERG and an anti-AR
antibody.
(D) Representative genes co-occupied by AR and ERG. On the y axes are the number of reads of AR (left, in blue) and ERG (right, in red) binding sites. Above the
plot are the TSS and direction denoted by arrows, exons by black box, and introns by horizontal lines, respectively. The genomic coordinates are indicated below
the plot.
(E) ChIP-PCR confirms AR and ERG co-occupancy on selected genes. The y axis on the left represents AR ChIP enrichment in VCaP cells treated with R1881
normalized to the ethanol (Ethl) treated cells. The y axis on the right represents ChIP enrichment (in log scale) by an anti-ERG antibody normalized to IgG. Error
bars represent n = 3, mean and standard error of the mean (SEM). The 30 intronic region of the KIAA0066 gene was used as a negative control.
(F) AR and ERG co-occupancy in a prostate cancer tissue. A prostate tumor tissue that expresses both AR and TMPRSS2-ERG were analyzed by ChIP-Seq.
(G) Physical interaction between the AR and ERG proteins. VCaP cells were immunoprecipitated by various antibodies and immunoblotted for AR. To deplete
DNA, VCaP cell lysates were preincubated with ethidium bromide for 30 min before immunoprecipitation. Representative experiment of four independent coim-
munoprecipitation assessments is shown.
(H) Interaction of ERG with AR in vitro via the ETS domain. HaloTag-ERG protein and mutants were generated by in vitro transcription/translation in wheat germ
extracts. Recombinant GST-AR was incubated with the in vitro translated protein products and glutathione beads used in pull-down assays. The interaction
between AR and various domains of ERG are summarized and indicated as + or . See also Figure S3 and Table S5.
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ERG Disrupts AR Lineage-Specific DifferentiationThe TMPRSS2-ERG Gene Fusion Product Disrupts
Androgen Signaling
Interestingly, one of the top genomic loci bound by ERG was the
promoter of the AR gene as illustrated by ChIP-Seq and
confirmed by ChIP-PCR (Figures 4A and 4B). By overexpressing
ERG we observed significantly decreased AR transcript in
multiple prostate cell lines, including the VCaP and LNCaP pros-tate cancer cells and the immortalized RWPE prostate epithelial
cells (Figure 4C). Concordantly, knockdown of ERG in VCaP cells
led to AR upregulation, further supporting an inhibitory role of
ERG on the AR gene (Figures S4A and S4B). In addition, we
observed a marked decrease of AR protein following ERG over-
expression in the LNCaP and VCaP prostate cancer cells as well
as in the 22RV1 cells that are free of ETS family gene fusions,Cancer Cell 17, 443–454, May 18, 2010 ª2010 Elsevier Inc. 447
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Figure 4. ERG Negatively Regulates the AR Gene
(A) ChIP-Seq showing AR and ERG cobinding to the regulatory regions of the AR gene. The y axes are as denoted as in Figure 3D.
(B) ChIP-PCR confirms ERG binding to the AR promoter. Error bars represent n = 3, mean ± SEM.
(C) Ectopic ERG overexpression represses the AR transcript. VCaP and LNCaP prostate cancer cells and RWPE benign prostate epithelial cells were infected by
LacZ or ERG adenovirus. QRT-PCR was used to assay the ERG and AR transcript normalized to GAPDH. Error bars represent n = 3, mean ± SEM.
(D) ERG represses the AR protein. VCaP (in the presence or absence of androgen R1881), LNCaP, RWPE, and 22RV1 cells were infected with ERG for 48 hr before
immunoblotting.
(E) ERG knockdown derepresses the AR protein. RNA interference of ERG was done in VCaP cells in the presence or absence of androgen. See also Figure S4.
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ERG Disrupts AR Lineage-Specific Differentiationwhereas AR protein was expectedly not detected in the RWPE
cells (Figure 4D and Figure S4C). Consistent with this, RNA inter-
ference of ERG in the hormone-starved VCaP cells greatly
increased AR protein (Figure 4E). Adding androgen to these cells
dramatically increased ERG expression, as expected. AR levels,
however, were decreased, further demonstrating a negative reg-
ulation. Moreover, we showed that ERG overexpression greatly
reduced AR promoter reporter activity in LNCaP cells (Fig-
ure S4D). In addition, AR and ERG expression were significantly
anticorrelated (r = 0.35, p = 0.001) in vivo in localized prostate
tumors (Figure S4E).
Besides directly regulating AR itself, ERG was recruited to
a majority of AR target genes at gene-specific loci, for instance
KLK3, KLK2, SLC45A3, and FKBP5 (Figure 5A). We thus ana-
lyzed AR target gene expression in 67 localized prostate tumors
that were classified into either ERG-positive (ERG+) or ETS-
negative (ETS) depending on the status of ETS family gene
fusions. ETS tumors were used as a negative control for com-
parison so as to preclude any effects from non-ERG ETS family
gene fusions. Importantly, GSEA analysis demonstrated signifi-
cant enrichment (p < 0.001) of ‘‘genes induced by androgen’’
in the gene set that is ‘‘repressed in ERG+ relative to ETS pros-448 Cancer Cell 17, 443–454, May 18, 2010 ª2010 Elsevier Inc.tate tumors,’’ thus linking androgen induction with ERG repres-
sion (Figure 5B). For example, KLK3, TMPRSS2, KLK2, and
KLK4 were all expressed at significantly lower levels in the
ERG+ than the ETS prostate tumors (Figure S5A). This is an
interesting finding that is consistent with our overall hypothesis
that ERG functions to repress androgen regulation of a lineage-
specific differentiation program. To further confirm this, we over-
expressed ERG in LNCaP cells and carried out quantitative
reverse-transcription polymerase chain reaction (qRT-PCR)
analysis of a set of known androgen-induced genes, many of
which are markers of prostate epithelial differentiation. Impor-
tantly, our results showed marked inhibition of these genes,
while ERG expectedly activated other targets such as PLAT
and PLAU (Tomlins et al., 2008) (Figure 5C). Similar suppression
of androgen signaling by ERG was also observed in the 22RV1
cells that are negative for ETS family gene fusions (Figure S5B).
We next investigated whether RNA interference of ERG may
rescue this inhibition using the TMPRSS2-ERG-positive VCaP
cells. We first treated hormone-starved VCaP cells with andro-
gen and confirmed androgen-induced expression of AR target
genes. Remarkably, the expression of these genes can be further
increased by RNA interference of ERG, confirming endogenous
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Figure 5. ERG Attenuates AR Transcriptional Activity
(A) ChIP-Seq showing AR and ERG cobinding to the regulatory regions of representative AR target genes. The y axes are as denoted in Figure 3D.
(B) Androgen-induced genes are significantly enriched for repression by ERG. Androgen-induced genes were obtained from microarray analysis of time-course
androgen treatment of LNCaP cells. ERG-repressed genes are downregulated in the ERG+ (n = 35) relative to the ETS (n = 31) prostate tumors based on cancer
gene expression microarray profiling.
(C) ERG overexpression represses AR target genes. LNCaP cells were infected with ERG or lacZ for 48 hr prior to qRT-PCR analysis. ERG, PLAT, and PLAUwere
used as positive controls for ERG overexpression.
(D) ERG knockdown derepresses androgen-induced genes. VCaP cells were hormone starved for 2 days and treated with ethanol, synthetic androgen R1881, or
R1881 with concurrent RNA interference targeting ERG for 48 hr before qRT-PCR analysis. The level of ERG knockdown is shown in Figure S4B.
(E) Suppression of the KLK3 and TMPRSS2 promoters by ERG. LNCaP cells were cotransfected with various promoter reporter constructs along with pRL-TK
(the internal control) at 24 hr postinfection of ERG or LacZ, incubated for another 24 hr, and then monitored for luciferase activity. Error bars represent n = 3,
mean ± SEM. See also Figure S5.
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ERG Disrupts AR Lineage-Specific DifferentiationERG suppression of androgen response in the VCaP cells that
can be derepressed by removing ERG (Figure 5D).
ChIP-PCR analysis of LNCaP cells following ERG titration
revealed gradually increased ERG binding, but decreased AR
binding, on these gene-specific genomic loci, supporting direct
regulation by ERG independent of AR (Figures S5C and S5D).
Consistent with this, ChIP-Seq analysis of VCaP cells following
RNA interference of ERG revealed a 24% decrease in the num-
ber of ERG binding sites and a 26% increase in AR binding sites.
Further, ERG overexpression in cells with either AR knockdown
or AR overexpression continued to inhibit AR target genes
(Figures S5E and S5F). Furthermore, luciferase reporter assays
demonstrated substantially reduced (5-fold) promoter activi-
ties of the KLK3 and TMPRSS2 gene by ERG overexpression
(Figure 5E). Therefore, ERG disrupts androgen signaling through
multiple mechanisms including by inhibiting AR expression,
binding to and repressing AR downstream targets at gene-
specific loci.
We next examined the oncogenic role of TMPRSS2-ERG
gene fusions in the context of androgen signaling. Interestingly,
ectopic overexpression of ERG in VCaP and LNCaP prostatecancer cells remarkably increased cell invasion in the presence
or absence of androgen, independent of AR (Figures 6A and 6B).
Similarly, ERG overexpression dramatically induced cell prolifer-
ation, independent of androgen as well as AR protein expression
(Figures 6C–6E). We therefore tested if ERG is able to drive
androgen-independent prostate cancer cell growth. Stable
clones of VCaP cells expressing ERG (VCaP+ERG) or the GUS
control gene (VCaP+GUS) were selected and assayed for cell
proliferation. Remarkably, we observed that the VCaP+ERG
cells grow significantly faster than the VCaP+GUS cells (Fig-
ure 6F). In addition, the VCaP+ERG cells were able to con-
tinuously proliferate in the absence of androgen, while the
VCaP+GUS cells failed to grow (Figure 6G). Therefore, by inhib-
iting AR-mediated prodifferentiation and regulating AR-indepen-
dent oncogenesis TMPRSS2-ERG may provide a potential
mechanism for androgen resistance.
TMPRSS2-ERG Induces EZH2-Mediated
Epigenetic Silencing
By MCM analysis we have earlier shown a link of ERG
and androgen signaling with Polycomb-mediated H3K27Cancer Cell 17, 443–454, May 18, 2010 ª2010 Elsevier Inc. 449
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Figure 6. ERG Regulates the Neoplastic Properties of Prostate Cancer Cells Independent of Androgen Signaling
(A) Ectopic ERG overexpression induces prostate cancer cell invasion in the absence of androgen. The VCaP and LNCaP prostate cancer were hormone-starved
for 1 day, and infected with ERG or control for another 2 days in the absence of androgen.
(B) Ectopic ERG overexpression induces prostate cancer cell invasion independent of AR. VCaP and LNCaP cells were subjected to RNA interference against AR
or control for 1 day before adenovirus infection of ERG or LacZ.
(C) Ectopic ERG overexpression induces VCaP cell growth independent of androgen. VCaP cells were hormone deprived for 48 hr before infection with LacZ or
ERG adenovirus in the presence or absence of androgen.
(D, E) Ectopic ERG overexpression induces prostate cancer cell growth independent of AR expression. VCaP and LNCaP cells were subjected to RNA interfer-
ence targeting AR or control for 1 day before adenovirus infection by ERG or LacZ. Cell proliferation was assayed at 48 hr or 96 hr after infection.
(F) Ectopic ERG overexpression in prostate cancer cells increases cell growth. VCaP cells were infected with lentivirus expressing ERG or GUS (control). Stable
clones expressing ERG (VCaP+ERG) or control (VCaP+GUS) were plated equally, and assayed for cell proliferation in regular medium.
(G) Ectopic ERG overexpression confers cell growth in the absence of AR signaling. Equal numbers of stable VCaP+ERG and control cells were hormone-
deprived for 48 hr and assayed for cell proliferation in hormone-deprived medium.
Error bars represent n = 3, mean ± SEM.
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ERG Disrupts AR Lineage-Specific Differentiationmethylation, which has been shown to prevent the differen-
tiation of embryonic stem cells and contribute to tumor cell
dedifferentiation (Boyer et al., 2006; Lee et al., 2006; Yu
et al., 2007b) (Figure 1C). We thus hypothesized that, besides
inhibiting AR-mediated prodifferentiation, ERG may potenti-
ate pathways involving H3K27me3 to control cell dedif-
ferentiation. Indeed, whereas AR and H3K27me3 binding sites
rarely overlap (<2%) in LNCaP, there was substantially more
overlap (13%) in VCaP, probably due to the recruitment by
ERG (Figures S6A and S6B). To test this, we investigated
ERG regulation of the H3K27 methyltransferase EZH2. Inter-
estingly, ChIP-Seq analysis revealed ERG binding to the
EZH2 promoter, which was confirmed by ChIP-PCR (Figures
7A and 7B). In addition, RNA interference of ERG greatly
decreased EZH2 expression (Figure 7C). Concordant with
this, ERG overexpression in LNCaP and RWPE cells markedly
induced EZH2 (Figure 7D). Further, EZH2 and ERG expression
were positively correlated (r = 0.23, p = 0.043) in clinically
localized prostate tumors. EZH2 expression was significantly
higher (p < 0.001) in the ERG+ (n = 35) than the ETS (n = 31)
tumors, thus supporting a model in which ERG activates EZH2
(Figure 7E).
We next investigated if ERG regulates EZH2-mediated epige-
netic silencing. ChIP-Seq analysis demonstrated ERG binding to
a number of previously reported EZH2 target genes such as
ADRB2, CDH1, DAB2IP, SNCA, and SOCS (Cao et al., 2008;
Chen et al., 2005; Yu et al., 2007b) (Figure S6B). Remarkably,
whereas ERG activated EZH2 expression, it strongly repressed450 Cancer Cell 17, 443–454, May 18, 2010 ª2010 Elsevier Inc.the expression of EZH2 target genes, thus supporting ERG acti-
vation of EZH2-mediated epigenetic silencing in prostate cancer
(Figure 7F and Figure S6C). In addition, silencing of EZH2
restored the expression of EZH2 target genes such as DAB2IP,
loss of which was recently shown leading to epithelial-to-mesen-
chymal transition and cellular maldifferentiation (Figure S6D)
(Min et al., 2010; Xie et al., 2010). To further test a genome-
wide association between ERG and EZH2-mediated dedifferen-
tiation pathways, we investigated whether the expression
pattern of PcG target genes are able to predict the status of
TMPRSS2-ERG gene fusions in prostate tumors. We first
derived previously reported Polycomb gene signatures associ-
ated with ESCs and poorly differentiated tumors, including
target genes of Polycomb repressive complex 2 (PRC2), of
PcG proteins SUZ12 and EED, and of H3K27me3 (Ben-Porath
et al., 2008). We then analyzed the power of these gene
signatures in predicting the status of TMPRSS2-ERG gene
fusions in clinically localized prostate tumors. Importantly,
the expression pattern of all PcG-related gene signatures accu-
rately predicted the ERG status, whereas irrelevant control gene
sets, including the target genes of histone H3, PolII, H3K36me3,
and H3K4me3, were significantly (p < 0.001) less predictive
(Figure 7G). Notably, androgen-induced genes (presumably
repressed by ERG) also successfully predicted ERG status in
prostate tumors. Therefore, ERG may have more global
effects by disrupting androgen-mediated prostatic differentia-
tion and inducing EZH2-mediated cellular dedifferentiation
(Figure 7H).
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Figure 7. ERG Induces EZH2-Mediated Epigenetic Silencing
(A, B) ChIP-Seq and ChIP-PCR shows ERG binding to the EZH2 promoter in VCaP cells. Error bars represent n = 3, mean ± SEM.
(C) ERG knockdown in VCaP cells decreases EZH2 protein.
(D) ERG overexpression increases EZH2 protein. LNCaP and RWPE cells were infected with ERG or LacZ adenovirus for 48 hr before immunoblot analysis.
(E) EZH2 is expressed at significantly (p < 0.001) higher levels in the ERG+ (n = 35) than the ETS (n = 31) prostate tumors.
(F) ERG overexpression in the LNCaP cells activates EZH2 and represses known EZH2 target genes. LNCaP cells were infected with LacZ or ERG adenovirus for
48 hr and analyzed by qRT-PCR. Error bars represent n = 3, mean ± SEM. See also Figure S6.
(G) Polycomb-related signatures and androgen-induced genes predict the status of TMPRSS2-ERG gene fusion in localized prostate tumors. The target genes of
PcG proteins in embryonic stem cells were derived from a previous study (Ben-Porath et al., 2008), while the control gene signatures were taken from the ChIP-
Seq experiments. Androgen-induced or androgen-repressed genes were from microarray profiling of the LNCaP cells following androgen treatment. A random
signature not related to ERG (by removing ERG-regulated genes) was used as an absolute negative control (rand_nonERG). The Polycomb signatures and the
androgen-induced genes have prediction scores significantly (p < 0.001) better than the other gene sets.
(H) A model of TMPRSS2-ERG in prostate cancer by disrupting prostate-specific differentiation and potentiating a stem-cell-like dedifferentiation program. (i)
androgen signaling leads to normal prostate differentiation. (ii) Formation of the TMPRSS2-ERG somatic mutation. (iii) Inhibition of AR expression and direct inter-
action with AR by the TMPRSS2-ERG fusion product. (iv) ERG binding to AR target gene loci for negative regulation. (v and viii) Activation of epigenetic silencing,
stem-cell-like state, and oncogenesis. (vi) Induction of EZH2. (vii) Induction of H3K27 marks and epigenetic silencing of prodifferentiation genes.
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ERG Disrupts AR Lineage-Specific DifferentiationDISCUSSION
In the present study, we systematically mapped the genomic
landscape of AR, ERG, FoxA1, and RNA PolII, along with eight
critical histone marks in multiple prostate cancer cell lines as
well as in one prostate tumor specimen. These studies not only
reveal important biological findings regarding the mechanisms
of TMPRSS2-ERG gene fusions in prostate cancer, but they
also provide a compendium of 57 genome-wide ChIP-Seq
experiments and a large set of paired microarray expression
profiling data that will be useful for the investigation of biological
mechanisms of cancer and steroid hormone receptor signaling.
By analyzing these genome-wide maps, we provide a working
model of how TMPRSS2-ERG gene fusions regulate prostate
cancer progression. In the context of an androgen-regulated
gene fusion such as TMPRSS2-ERG, this fusion product can
attenuate androgen signaling by multiple, cooperative mecha-
nisms including direct inhibition of AR expression and attenua-
tion of AR signaling at gene-specific loci (Figure 7H). Further-
more, our study reveals an additional pathway of ERG in
perturbing cell differentiation through the Polycomb group
proteins. Enrichment of H3K27me3-marked genes silenced inESCs and aggressive tumors was first apparent by MCM anal-
ysis of AR-occupied genes in prostate cancer, linking both AR
and ERG to repressive epigenetic signatures (Figure 1C). This
was further substantiated in prostate cancer tissues harboring
ERG gene fusions being distinguishable by H3K27me3-contain-
ing and/or Polycomb-occupied genes. ERG was found to be
a direct activator of EZH2 and the level of EZH2 expression
was associated with the ERG status in a cohort of prostate
tumors (Figure 7). Thus, TMPRSS2-ERG plays a central role as
a ‘‘malignant regulatory switch’’ that shuts down androgen
signaling, inhibiting normal prostate differentiation and turning
on EZH2 expression, which induces an ESC-like dedifferentia-
tion program.
Because TMPRSS2-ERG gene fusions are androgen-respon-
sive, they were thought to merely represent one of many mutated
pathways emanating from AR signaling. Our results, however,
suggest that TMPRSS2-ERG plays a much more fundamental
role. As an early-onset genetic lesion, TMPRSS2-ERG gene
fusion may provide a mechanism for AR overexpression and
mutation in advanced prostate cancer. Antiandrogen treatments
such as bicalutamide (also called Casodex) or flutamide are
currently being used to treat advanced disease (Anderson,Cancer Cell 17, 443–454, May 18, 2010 ª2010 Elsevier Inc. 451
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ERG Disrupts AR Lineage-Specific Differentiation2003). Unfortunately, patients treated with these AR antagonists
often develop recurrent disease that is resistant to this therapy.
Tumors from men with castration-resistant metastatic prostate
cancer (CRMPC) often overexpress AR through multiple mecha-
nisms including AR amplification (Scher and Sawyers, 2005).
Repression of AR by TMPRSS2-ERG may provide a malignant
selection pressure contributing to recurrent tumors with AR
amplification. This is supported by our observation of a negative
correlation (r = 0.35, p = 0.0014) between AR and ERG expres-
sion in localized prostate tumors, but a positive correlation
(r = 0.30, p = 0.058) in metastatic prostate cancers. Further,
whereas AR amplification on its own is not sufficient to induce
hyperplastic lesions, overexpression of a CMV-promoter driven
AR (thus not susceptible to ERG repression, mimicking a
hormone-refractory state with AR amplification), together with
forced ERG overexpression, has recently been shown to pro-
mote the development of a more poorly differentiated, invasive
adenocarcinoma (Zong et al., 2009). This may also suggest
that therapies targeting AR may not produce a durable response
in prostate cancer patients when the underlying mutation may in
fact be TMPRSS2-ERG. Paradoxically, therapies employing
high-dose testosterone may have a beneficial effect transiently
by favoring a normal differentiation state. Consistent with this,
preclinical models suggest that high doses of exogenous testos-
terone inhibit prostate cancer growth while lows levels of testos-
terone promote tumor growth (Koivisto et al., 1997; Kokontis
et al., 1998). Recently, high doses of exogenous testosterone
have been shown to be safe in patients with CRMPC (Morris
et al., 2009). Bicalutamide and flutamide exhibit a partial
agonistic effect that may also promote normal prostate differen-
tiation, which is eventually overcome by TMPRSS2-ERG expres-
sion and consequent resistant disease.
Taken together, our findings provide a working model in which
TMPRSS2-ERG plays a critical role in cancer progression by dis-
rupting the AR lineage-specific differentiation program of the
prostate and favoring EZH2-mediated cellular dedifferentiation.
In addition, by inhibiting AR signaling, TMPRSS2-ERG may exert
a selective pressure for the development of prostate cancer that
is resistance to hormone-deprivation therapies. Furthermore,
our study provides a compendium of 57 ChIP-Seq experiments
of key transcription factors and histone modifications in prostate
cancer, which will be invaluable for prostate cancer and steroid
hormone research.EXPERIMENTAL PROCEDURES
Cell Culture and In Vitro Overexpression, Inhibition,
and Function Assays
LNCaP, VCaP, RWPE, and 22RV1 cell lines were obtained from ATCC and
cultured accordingly. Adenoviral and lentiviral constructs expressing ERG or
GUS control were generated as previously described by recombining pCR8-
ERG and a control entry clone (pENTR-GUS) (Invitrogen) with pAD/CMV/V5
and pLenti6/CMV/V5, respectively, using LR Clonase II (Invitrogen) (Tomlins
et al., 2008). The pENTR-GUS serves as a positive control for the LR recombi-
nation reaction and GUS refers to beta-Glucuronidase, a protein detectable by
either a fluorescent or blue substrate in the cells. VCaP cells were infected with
ERG or GUS lentiviruses, and stable clones expressing ERG (VCaP+ERG) or
GUS (VCaP+GUS) were selected.
For RNA interference, cells were treated with non-targeting siRNA
(D-001210-01), or siRNA specific to ERG (D-003886-01) or AR (J-003400)
from Dharmacon. For androgen treatment, cells were hormone starved for452 Cancer Cell 17, 443–454, May 18, 2010 ª2010 Elsevier Inc.2 to 3 days before treated with 1 nM R1881 for 48 hr (for expression assay)
or 10 nM R1881 for 16 hr (for ChIP). Cell proliferation and invasion assays
were carried out as previously described (Yu et al., 2007a).
ChIP and ChIP-Seq Assays
ChIP was carried out as previously described (Yu et al., 2007a) and detailed in
the Supplemental Information. Antibodies used include AR (no. 06-680),
H3K27me3 (no. 07-449), and Ace-H3 (no. 06-599) from Millipore; ERG
(SC354X, Santa Cruz); and H3K4me3 (ab8580), H3K9me3 (ab8898), H3K4me1
(ab8895), H3K4me2 (ab7766), H3K36me3 (ab9050), Pan-H3 (ab1791), FoxA1
(ab23738), and RNA PolII (ab817) from Abcam. ChIP DNA was prepared into
libraries and sequenced using the Genome Analyzer (Illumina) following manu-
facturer’s protocols. The raw sequencing image data were analyzed by the
Illumina analysis pipeline, aligned to the unmasked human reference genome
(NCBI v36, hg18) using ELAND (Illumina), which is further analyzed by HPeak
(http://www.sph.umich.edu/csg/qin/HPeak/ and Supplemental Information) to
identify enriched peak regions.
Quantitative RT-PCR
Quantitative RT-PCR was performed using Power SYBR Green Mastermix
(Applied Biosystems) on an Applied Biosystems 7300 Real Time PCR machine
as previously described (Yu et al., 2007a). All primers (listed in Supplemental
Information) were designed using Primer 3 and synthesized by Integrated
DNA Technologies.
In Vitro Protein Interaction Assay
ERG and its subdomains were cloned into pFN19A (HaloTag) vector (Promega,
Madison, WI) and expressed in TNT SP6 High-Yield Wheat Germ Reaction.
A total of 2.0 ml cell-free reaction containing the HaloTag fusion protein was
mixed with 8 ml HaloTag Biotin Ligand (final concentration 1 mM), and incu-
bated at room temperature (RT) for 30 min. The biotin-labeled samples were
separated on SDS gel and blotted using HRP-streptavidin to confirm Halo-
Tag fusion protein expression. In in vitro pull-down assay AR protein fragments
containing the DNA-binding and ligand-binding domains were expressed in
bacteria with GST-tag at N-terminal and purified by glutathione beads. A total
of 12.5 ml cell-free reaction containing HaloTag fusion proteins were incubated
with 100 ng GST-AR proteins in PBST (0.1% Tween) at 4C overnight. Ten
microliter HaloLink beads (Promega) were blocked in BSA at 4C overnight.
After three washes with phosphate-buffered saline, the beads were mixed
with Halo-ERG and incubated at RT for 1 hr. Halolink beads were then washed
with PBST for four times and eluted in SDS loading buffer. Proteins were sepa-
rated on SDS gel and blotted with anti-GST mAb (Sigma) to detect AR. Bare
HaloLink beads without HaloTag fusion proteins were used as negative
controls.
Luciferase Reporter Assay
Luciferase reporter assays were performed as previously described (Cao et al.,
2008). Briefly, LNCaP cells were infected with ERG or LacZ adenovirus. At
24 hr postinfection promoter-reporter constructs were cotransfected along
with pRL-TK (internal control). Cells were lysed with passive lysis buffer and
luciferase activities were monitored using dual luciferase assay system (Prom-
ega) after an additional 24 hr of incubation. Reporter constructs, pGL3-CDH1-
Luc, pGL3 PSA6.0-Luc, and pGL3-ALP-Luc were provided by Drs. Eric Fearon
(Hajra et al., 1999), Evan T. Keller (Mizokami et al., 2000), and Mitsutoki Hatta
(Hatta et al., 2002), respectively. TMPRSS2 (chr21:41,801,764-41,802,692)
and AR (chrX:66,679,691-66,680,682) promoters were PCR amplified and
subcloned into pGL4.14 vector (Promega) using Bgl2 and Hind3 enzymes.
Bioinformatics Analysis
Predefined motifs of transcription factors were searched using MatInspector
(Cartharius et al., 2005) (Genomatix). Overrepresentation of a motif in ChIP-
Seq binding sites was evaluated against control sequences randomly
collected from regions other than binding sites and the significance tested
by Fisher’s exact test. De novo motif was analyzed using MEME (Bailey and
Elkan, 1994). GSEA analysis was performed as detailed in the Supplemental
Information. MCM was performed using a query gene list to search for all
concepts available in the Oncomine database as previously described (Yu
et al., 2007b). Concepts with significant enrichment by the query concept
Cancer Cell
ERG Disrupts AR Lineage-Specific Differentiationwere exported into a table (see Table S4). Representative concepts were
selectively shown as a network in a figure (see Figure 1C).
ACCESSION NUMBERS
The microarray and short-read sequencing data have been deposited in the
National Center for Biotechnology Information Gene Expression Omnibus
and Short-Read Archive with the accession number GSE14097.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, five tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:
10.1016/j.ccr.2010.03.018.
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